Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2015-09-28

Clinical Trial Update: A Study of Oral Suberoylanilide Hydroxamic Acid (SAHA) in Patients With Malignant Lymphoma (0683-030) [Phase 1]

View source ↗

Summary

This update notes the completion of a Phase 1 trial evaluating oral SAHA (vorinostat) in patients with malignant lymphoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Vorinostat (vorinostat)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Lymphoma | Phase 1 | Status: COMPLETED